Search clinical trials for: INBRX-109

Total 4368 results

Inhibrx, Inc.

Recruiting

Study of INBRX-109 in Conventional Chondrosarcoma (ChonDRAgon)

Conventional Chondrosarcoma

United States, Spain, United Kingdom, France, Germany, Italy, Australia, Netherlands, Ireland
Inhibrx, Inc.

Completed

Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency (rhAAT-Fc)

Alpha-1 Antitrypsin Deficiency | AATD

United States, New Zealand, United Kingdom
PhotonMD, Inc

Completed

Modulated Light Therapy in Participants With Pattern Hair Loss

Androgenetic Alopecia

Australia
Inhibrx, Inc.

Not yet recruiting

Open Label Extension Study of INBRX-101 in Adults With AATD Emphysema (ELEVAATE OLE)

Emphysema | Alpha 1-Antitrypsin Deficiency
Providence Health & Services
Inhibrx, Inc.

Not yet recruiting

Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients

Triple Negative Breast Cancer

United States
Inhibrx, Inc.

Not yet recruiting

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Head and Neck Squamous Cell Carcinoma (HNSCC)
University of Oxford

Completed

A BCG Challenge Model Study to Assess Anti-mycobacterial Immunity Induced by BCG and a Candidate TB Vaccine, MVA85A

Tuberculosis

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Two-part Study of the Effects of MK-1029 in Allergen-Challenged Asthmatics (MK-1029-003)

Asthma
Inhibrx, Inc.

Recruiting

Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema (ELEVAATE)

Emphysema | Alpha 1-Antitrypsin Deficiency

United States, Australia, United Kingdom, New Zealand
Inhibrx, Inc.

Recruiting

Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer (PDL1x41BB)

Melanoma | Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Gastric Adenocarcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Adenocarcinoma | Metastatic Solid Tumors | Oropharyngeal Carcinoma

United States
Otsuka Pharmaceutical Co., Ltd.

Completed

A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer

Colorectal Cancer

Japan
ImmunityBio, Inc.

Not yet recruiting

IBRX-042 In Subjects With HPV-Associated Tumors

HPV-Related Carcinoma
Transwell Biotech Co., Ltd.

Completed

TWB-103 for Treating Lower Limb Ulcers on Patients With DM

Diabetic Foot Ulcer

Taiwan
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

United States
Inhibrx, Inc.
Merck Sharp & Dohme LLC

Recruiting

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Melanoma | Renal Cell Carcinoma | Head and Neck Cancer | Gastric Cancer | Non-Small Cell Lung Cancer | Solid Tumor | Urothelial Carcinoma

United States
Sunovion Respiratory Development Inc.

Completed

A Study of the Efficacy and Safety of EP-101 ( (SUN101) in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (GOLDEN-2)

COPD

United States
Inhibrx, Inc.

Recruiting

Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Sarcoma | Pancreatic Adenocarcinoma | Ewing Sarcoma | Gastric Adenocarcinoma | Chondrosarcoma | Solid Tumors | Malignant Pleural Mesothelioma | Colorectal Adenocarcinoma | GIST | SDH-deficient Solid Tumors

United States
RXi Pharmaceuticals, Corp.

Unknown

A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Revised Hypertrophic Scars

Hypertrophic Scar

United States, Honduras
Coronado Biosciences, Inc.

Unknown

CNDO-109-AANK for AML in First Complete Remission (CR1)

Acute Myeloid Leukemia

United States
Hunan Province Tumor Hospital

Completed

Antitumor Activity and Safety of BEBT-109, a Novel EGFR Inhibitor, in Previously Treated NSCLC

NSCLC

China
RXi Pharmaceuticals, Corp.

Unknown

Evaluating RXI-109 to Reduce the Progression of Subretinal Fibrosis in Subjects With NVAMD

Age-related Macular Degeneration | Subfoveal Choroidal Neovascularization | Subretinal Scarring | Subretinal Fibrosis

United States
Taiho Pharmaceutical Co., Ltd.

Terminated

Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer

Advanced Colorectal Cancer

United States
Lytix Biopharma AS

Completed

A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection

Atopic Dermatitis | Gram-positive, Skin Infections | Mild Eczema/Dermatoses

Hungary
M.D. Anderson Cancer Center

Recruiting

Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

Leukemia | Leukemia, Lymphoblastic

United States
CuraSen Therapeutics, Inc.

Active, not recruiting

A Study of CST-103 Co-administered With CST-107 in Subjects With Neurodegenerative Disorders (CLIN-011)

Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia

Australia, New Zealand, United Kingdom
CuraSen Therapeutics, Inc.

Not yet recruiting

A Study of CST-103 Co-administered With CST-107 in Subjects With Parkinson's Disease Having Freezing of Gait (CLIN-012)

Freezing of Gait Symptoms in Parkinson's Disease

Australia
RXi Pharmaceuticals, Corp.

Completed

A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults

Hypertrophic Scar

United States, Honduras
RXi Pharmaceuticals, Corp.

Completed

A Study to Evaluate the Effectiveness and Safety of RXI-109 on the Outcome of Keloid Excision Surgery in Healthy Adults

Keloid

United States, Dominican Republic
RXi Pharmaceuticals, Corp.

Completed

Evaluation of the Safety, Pharmacokinetics, and Preliminary Effect on Scar Formation by RXI-109

Cicatrix | Scar Prevention

United States
RXi Pharmaceuticals, Corp.

Completed

Evaluation of Safety, PK, and Preliminary Effects on Scar Formation of Multiple Intradermal Administrations of RXI-109

Cicatrix | Scar Prevention
PegBio Co., Ltd.
Covance

Completed

Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM)

United States
Seres Therapeutics, Inc.

Completed

ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection

Clostridioides Difficile Infection

United States, Canada
Lytix Biopharma AS

Completed

A Phase II Study to Evaluate the Efficacy and Safety of Two Doses of LTX-109 in Impetigo

Non-bullous Impetigo

Dominican Republic
International Partnership for Microbicides, Inc.
Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaborators

Recruiting

PK, Safety Study of 90-Day Use of Vaginal Rings Containing Dapivirine and Levonorgestrel

Bleeding | Pharmacokinetics | Safety Issues

United States
Mustang Bio

Enrolling by invitation

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Diffuse Large B Cell Lymphoma | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Hairy Cell Leukemia | Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Chronic Lymphocytic Leukemia in Relapse | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma and other conditions

United States
Shanghai Simnova Biotechnology Co.,Ltd.
Chinese PLA General Hospital

Recruiting

The Safety and Efficacy of SNC-109 CAR-T Cells Therapy the Recurrent Glioblastoma

Recurrent Glioblastoma Multiforme

China
Emory University
National Cancer Institute (NCI); Genentech, Inc.; National Institutes of Health...

Active, not recruiting

Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma | CCND1 Positive | t(11;14) Positive

United States
Pharma Holdings AS
University Hospital of North Norway

Completed

LTX-109 as Treatment for Hidradenitis Suppurativa

Hidradenitis Suppurativa

Norway
Duke University
National Institute on Drug Abuse (NIDA)

Recruiting

Low Nicotine Cigarettes, Smoking, and Chronic Pain (VLNCPain)

Chronic Pain | Smoking, Cigarette

United States
Betta Pharmaceuticals Co., Ltd.

Not yet recruiting

Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation

Non-Small Cell Lung Cancer、EGFR Sensitive Mutation

China
Yonsei University

Completed

Lower Femtosecond Laser Energy Levels Lead to Better Visual Recovery After Small-incision Lenticule Extraction for Myopia

Myopia

Korea, Republic of
Seres Therapeutics, Inc.

Approved for marketing

Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)

Clostridioides Difficile Infection
Seres Therapeutics, Inc.

Completed

ECOSPOR III - SER-109 Versus Placebo in the Treatment of Adults With Recurrent Clostridium Difficile Infection (ECOSPORIII)

Clostridium Difficile Infection

United States, Canada
National Center for Research Resources (NCRR)
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease

Cytomegalovirus Infections
International AIDS Vaccine Initiative
Coalition for Epidemic Preparedness Innovations

Recruiting

A Lassa Fever Vaccine Trial in Adults and Children Residing in West Africa

Lassa Fever

Ghana, Liberia, Nigeria
Pharma Holdings AS
CTC Clinical Trial Consultants AB

Completed

A Study to Evaluate the Safety and Efficacy of 3% LTX-109 for Nasal Decolonisation of Staphylococcus

Nasal Decolonization of Staphylococcus Aureus

Sweden
Ente Ospedaliero Ospedali Galliera

Active, not recruiting

Ferrochelating Treatment in Patients Affected by Neurodegeneration With Brain Iron Accumulation (NBIA)

Iron Overload | Neurodegenerative Disease

Italy
Teva Pharmaceuticals USA
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study to Test if TVB-009P is Effective in Relieving Postmenopausal Osteoporosis

Osteoporosis, Postmenopausal

United States, Bulgaria, Czechia, Georgia, Germany, Hungary, Poland, Russian Federation, Slovakia, Ukraine
Santen Inc.

Terminated

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

Non Infectious Uveitis

United States, India, Italy, Argentina
Pharma Holdings AS
CTC Clinical Trial Consultants AB

Completed

Study to Evaluate the Efficacy, Safety and Tolerability of 3% LTX-109 for Nasal Decolonisation of Staphylococcus Aureus

Nasal Decolonization of Staphylococcus Aureus

Sweden

Search clinical trials for: INBRX-109

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations